Remimazolam enabled safe anesthetic management during tracheostomy in a patient with amyotrophic lateral sclerosis: a case report

Background Amyotrophic lateral sclerosis (ALS) is known to cause generalized muscle atrophy and respiratory complications.

Anesthetic agents and methods for patients with ALS are extremely important because they critically influence postoperative outcomes.

In this clinical case, we mainly used remimazolam for safe anesthesia management.

Case presentation A 66-year-old man had a gradual onset of numbness and weakness in his extremities over 2 years.

He was diagnosed with ALS after the appearance of dysarthria and restrictive ventilation disorder.

Due to the rapid progression of respiratory dysfunction, the patient was placed on artificial respiration, and a tracheostomy was planned.

General anesthesia was induced with remimazolam (6 mg/kg/h) and remifentanil (0.5 μg/kg/min).

Tracheal intubation was performed without muscle relaxants, followed by total intravenous anesthesia (TIVA) with continuous administration of remimazolam 0.8–1.2 mg/kg/h and remifentanil 0.3–0.5 μg/kg/min.

At the end of the surgery, the anesthetic effect of remimazolam was reversed with 0.4 mg of flumazenil.

The patient was discharged from the operating room with stable breathing, and changes to preoperative ventilator settings were not necessary.

Conclusions We safely performed tracheostomy for a patient with ALS using remimazolam during general anesthesia.